Falko Fend
High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML).
Bajrami Saipi M, Ruiba A, Schittenhelm M, Blumenstock G, Győrffy B, Fazio S, Hafner M, Ahrens A, Aldinger L, Aellig V, Kavelaars F, Nombela-Arrieta C, Fend F, Valk P, Driessen C, Kampa-Schittenhelm K. High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML). Cell Death Dis 2024; 15:869.
30.11.2024High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML).
30.11.2024Cell Death Dis 2024; 15:869
Bajrami Saipi Mihada, Ruiba Alessia, Schittenhelm Marcus, Blumenstock Gunnar, Győrffy Balázs, Fazio Serena, Hafner Marlon, Ahrens Anna-Lena, Aldinger Lara, Aellig Vanessa, Kavelaars François G, Nombela-Arrieta César, Fend Falko, Valk Peter J M, Driessen Christoph, Kampa-Schittenhelm Kerstin
Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
Tsintari V, Walter B, Fend F, Overkamp M, Rothermundt C, Lopez C, Schittenhelm M, Kampa-Schittenhelm K. Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS). BMC cancer 2022; 22:725.
02.07.2022Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
02.07.2022BMC cancer 2022; 22:725
Tsintari Vasileia, Walter Bianca, Fend Falko, Overkamp Mathis, Rothermundt Christian, Lopez Charles D, Schittenhelm Marcus, Kampa-Schittenhelm Kerstin
ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
Rieger I, Tsintari V, Overkamp M, Fend F, Lopez C, Schittenhelm M, Kampa-Schittenhelm K. ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis. Front Mol Biosci 2021; 8:727203.
05.11.2021ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
05.11.2021Front Mol Biosci 2021; 8:727203
Rieger Ingmar, Tsintari Vasileia, Overkamp Mathis, Fend Falko, Lopez Charles D, Schittenhelm Marcus, Kampa-Schittenhelm Kerstin
The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma
Hartmann S, Hansmann M, Engert A, Rosenwald A, Möller P, Klapper W, Stein H, Quintanilla-Martinez L, Fend F, Cogliatti S, Ott G, Feller A, Bernd H, Mottok A, Plütschow A, Eichenauer D. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. Am J Hematol 2019; 94:1208-1213.
21.08.2019The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma
21.08.2019Am J Hematol 2019; 94:1208-1213
Hartmann Sylvia, Hansmann Martin-Leo, Engert Andreas, Rosenwald Andreas, Möller Peter, Klapper Wolfram, Stein Harald, Quintanilla-Martinez Leticia, Fend Falko, Cogliatti Sergio B., Ott German, Feller Alfred C, Bernd Heinz-Wolfram, Mottok Anja, Plütschow Annette, Eichenauer Dennis A
Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia
Schittenhelm M, Lopez C, Fend F, Mau-Holzmann U, Illing B, Akmut F, Bajrami Saipi M, Federmann B, Tsintari V, Walter B, Kampa-Schittenhelm K. Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia. EBioMedicine 2019; 42:340-351.
02.04.2019Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia
02.04.2019EBioMedicine 2019; 42:340-351
Schittenhelm Marcus, Lopez Charles Darin, Fend Falko, Mau-Holzmann Ulrike, Illing Barbara, Akmut Figen, Bajrami Saipi Mihada, Federmann Birgit, Tsintari Vasileia, Walter Bianca, Kampa-Schittenhelm Kerstin
Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
Kampa-Schittenhelm K, Vogel W, Bonzheim I, Fend F, Horger M, Kanz L, Soekler M, Schittenhelm M. Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia. Oncotarget 2018; 9:11876-11882.
31.01.2018Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
31.01.2018Oncotarget 2018; 9:11876-11882
Kampa-Schittenhelm Kerstin, Vogel Wichard, Bonzheim Irina, Fend Falko, Horger Marius, Kanz Lothar, Soekler Martin, Schittenhelm Marcus
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
von Minckwitz G, Zahm D, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, du Bois A, Blohmer J, Müller B, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Denkert C. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29:2150-7.
25.04.2011Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
25.04.2011J Clin Oncol 2011; 29:2150-7
von Minckwitz Gunter, Zahm Dirk-Michael, Khandan Fariba, Hoffmann Gerald, Gerber Bernd, Eidtmann Holger, Fend Falko, Dietel Manfred, Mehta Keyur, du Bois Andreas, Blohmer Jens Uwe, Müller Berit Maria, Loibl Sibylle, Budczies Jan, Hanusch Claus, Darb-Esfahani Silvia, Hilfrich Jörn, Weiss Erich, Huober Jens, Denkert Carsten
Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment
Graf N, Dechow T, Schwaiger M, Peschel C, zum Büschenfelde C, Senekowitsch-Schmidtke R, Wester H, Schuster T, Fend F, Den Hollander J, Herrmann K, Buck A. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol 2008; 10:349-55.
14.08.2008Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment
14.08.2008Mol Imaging Biol 2008; 10:349-55
Graf Nicolas, Dechow Tobias, Schwaiger Markus, Peschel Christian, zum Büschenfelde Christian Meyer, Senekowitsch-Schmidtke Reingard, Wester Hans-Jürgen, Schuster Tibor, Fend Falko, Den Hollander Jürgen, Herrmann Ken, Buck Andreas K